NCT06686108View on ClinicalTrials.gov

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

PHASE2RecruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2028

Conditions
T-cell Acute Lymphoblastic LeukemiaALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONRelapse
Interventions
DRUG

Azacitidine (AZA) Days 1 - 5

Azacitidine, ih, 32mg/m2/d, days 1-5 of each 28-day cycle

DRUG

Decitabine (DAC)

decitabine, 5mg/m2/d, days 1-5 of each 28-day cycle.

DRUG

Venetoclax

venetoclax, 400mg/d, days 1-7 of each 28-day cycle

Trial Locations (1)

Unknown

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER